General Information of Drug Therapeutic Target (DTT) (ID: TT6PKBN)

DTT Name Proto-oncogene c-Src (SRC)
Synonyms pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src
Gene Name SRC
DTT Type
Successful target
[1]
BioChemical Class
Kinase
UniProt ID
SRC_HUMAN
TTD ID
T85943
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.10.2
Sequence
MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAAE
PKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGD
WWLAHSLSTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNAENPRGTFLVRES
ETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLVAYYSKHADGL
CHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTL
KPGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGETGKY
LRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYT
ARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVER
GYRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQPGENL
Function
Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Involved in anchorage-independent cell growth. Required for podosome formation. Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors.
KEGG Pathway
ErbB signaling pathway (hsa04012 )
Rap1 signaling pathway (hsa04015 )
Chemokine signaling pathway (hsa04062 )
Endocytosis (hsa04144 )
VEGF signaling pathway (hsa04370 )
Focal adhesion (hsa04510 )
Adherens junction (hsa04520 )
Tight junction (hsa04530 )
Gap junction (hsa04540 )
Platelet activation (hsa04611 )
GABAergic synapse (hsa04727 )
Inflammatory mediator regulation of TRP channels (hsa04750 )
Regulation of actin cytoskeleton (hsa04810 )
GnRH signaling pathway (hsa04912 )
Estrogen signaling pathway (hsa04915 )
Prolactin signaling pathway (hsa04917 )
Thyroid hormone signaling pathway (hsa04919 )
Oxytocin signaling pathway (hsa04921 )
Bacterial invasion of epithelial cells (hsa05100 )
Epithelial cell signaling in Helicobacter pylori infection (hsa05120 )
Shigellosis (hsa05131 )
Tuberculosis (hsa05152 )
Hepatitis B (hsa05161 )
Viral carcinogenesis (hsa05203 )
Proteoglycans in cancer (hsa05205 )
Reactome Pathway
Nuclear signaling by ERBB4 (R-HSA-1251985 )
Downregulation of ERBB4 signaling (R-HSA-1253288 )
PIP3 activates AKT signaling (R-HSA-1257604 )
Spry regulation of FGF signaling (R-HSA-1295596 )
Signaling by SCF-KIT (R-HSA-1433557 )
Regulation of KIT signaling (R-HSA-1433559 )
p38MAPK events (R-HSA-171007 )
Signaling by EGFR (R-HSA-177929 )
GAB1 signalosome (R-HSA-180292 )
Downstream signal transduction (R-HSA-186763 )
Regulation of gap junction activity (R-HSA-191650 )
Signaling by ALK (R-HSA-201556 )
FCGR activation (R-HSA-2029481 )
PECAM1 interactions (R-HSA-210990 )
Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530 )
EPH-Ephrin signaling (R-HSA-2682334 )
Integrin signaling (R-HSA-354192 )
GRB2 (R-HSA-354194 )
p130Cas linkage to MAPK signaling for integrins (R-HSA-372708 )
NCAM signaling for neurite out-growth (R-HSA-375165 )
CD28 co-stimulation (R-HSA-389356 )
CTLA4 inhibitory signaling (R-HSA-389513 )
Signal regulatory protein family interactions (R-HSA-391160 )
EPHB-mediated forward signaling (R-HSA-3928662 )
EPHA-mediated growth cone collapse (R-HSA-3928663 )
Ephrin signaling (R-HSA-3928664 )
EPH-ephrin mediated repulsion of cells (R-HSA-3928665 )
G alpha (s) signalling events (R-HSA-418555 )
ADP signalling through P2Y purinoceptor 1 (R-HSA-418592 )
G alpha (i) signalling events (R-HSA-418594 )
DCC mediated attractive signaling (R-HSA-418885 )
Netrin mediated repulsion signals (R-HSA-418886 )
Regulation of commissural axon pathfinding by SLIT and ROBO (R-HSA-428542 )
GP1b-IX-V activation signalling (R-HSA-430116 )
Recycling pathway of L1 (R-HSA-437239 )
VEGFA-VEGFR2 Pathway (R-HSA-4420097 )
Thrombin signalling through proteinase activated receptors (PARs) (R-HSA-456926 )
VEGFR2 mediated cell proliferation (R-HSA-5218921 )
CLEC7A (Dectin-1) signaling (R-HSA-5607764 )
RHO GTPases Activate Formins (R-HSA-5663220 )
RAF activation (R-HSA-5673000 )
MAP2K and MAPK activation (R-HSA-5674135 )
Signaling by moderate kinase activity BRAF mutants (R-HSA-6802946 )
Signaling by high-kinase activity BRAF mutants (R-HSA-6802948 )
Signaling by BRAF and RAF1 fusions (R-HSA-6802952 )
Paradoxical activation of RAF signaling by kinase inactive BRAF (R-HSA-6802955 )
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling (R-HSA-6811558 )
Cyclin D associated events in G1 (R-HSA-69231 )
RET signaling (R-HSA-8853659 )
MET activates PTK2 signaling (R-HSA-8874081 )
InlA-mediated entry of Listeria monocytogenes into host cells (R-HSA-8876493 )
Regulation of RUNX1 Expression and Activity (R-HSA-8934593 )
Receptor Mediated Mitophagy (R-HSA-8934903 )
RUNX2 regulates osteoblast differentiation (R-HSA-8940973 )
Regulation of RUNX3 expression and activity (R-HSA-8941858 )
Extra-nuclear estrogen signaling (R-HSA-9009391 )
RHOU GTPase cycle (R-HSA-9013420 )
Activated NTRK2 signals through FYN (R-HSA-9032500 )
Activated NTRK3 signals through PI3K (R-HSA-9603381 )
Long-term potentiation (R-HSA-9620244 )
GPER1 signaling (R-HSA-9634597 )
Signaling downstream of RAS mutants (R-HSA-9649948 )
Signaling by RAF1 mutants (R-HSA-9656223 )
FCGR3A-mediated IL10 synthesis (R-HSA-9664323 )
FCGR3A-mediated phagocytosis (R-HSA-9664422 )
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants (R-HSA-9670439 )
Signaling by ERBB2 (R-HSA-1227986 )
BioCyc Pathway
MetaCyc:HS02256-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
4 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [2]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [2]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [1]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [3]
------------------------------------------------------------------------------------
11 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AL3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [4]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [4]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [5]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [6]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [7]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [9]
KX2-361 DML4H05 Brain cancer 2A00 Phase 1 [10]
PUR1800 DM6H10N Chronic obstructive pulmonary disease CA22 Phase 1 [11]
SUN-K0706 DMIF8RY Chronic lymphocytic leukaemia 2A82.0 Phase 1 [4]
TPX-0022 DMC2IJN Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
9 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aromatic bicyclic compound 1 DMVLQ2P N. A. N. A. Patented [13]
Aromatic bicyclic compound 2 DMKFV67 N. A. N. A. Patented [13]
Aromatic bicyclic compound 3 DMRXN94 N. A. N. A. Patented [13]
Aromatic bicyclic compound 4 DM3E75P N. A. N. A. Patented [13]
Aromatic bicyclic compound 5 DMALF06 N. A. N. A. Patented [13]
Aromatic bicyclic compound 6 DM8L3KM N. A. N. A. Patented [13]
Deuterated 3-cyanoquinoline derivative 1 DM3Q9OX N. A. N. A. Patented [14]
PMID28460551-Compound-6 DMT7U1O N. A. N. A. Patented [15]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Patented Agent(s)
2 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AP22408 DM5B72D Osteoporosis FB83.0 Terminated [17]
PD166285 DMAOHXY N. A. N. A. Terminated [18]
------------------------------------------------------------------------------------
98 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE DM2XFGJ Discovery agent N.A. Investigative [19]
3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol DMLYVPH Discovery agent N.A. Investigative [20]
4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine DMI580M Discovery agent N.A. Investigative [21]
5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol DMKXIWQ Discovery agent N.A. Investigative [21]
7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine DMU74R8 Discovery agent N.A. Investigative [20]
A-420983 DM7HSCI Discovery agent N.A. Investigative [22]
A-770041 DMP78JY Discovery agent N.A. Investigative [23]
Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr DMH0SQC Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr DMG19LW Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2) DMORPDV Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr DMK7YIG Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr DMUWI2F Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr DMNW7GR Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr DMO4MYI Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr DME4FZD Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2) DM856JM Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe DMU2PT1 Discovery agent N.A. Investigative [24]
Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2) DM4MP69 Discovery agent N.A. Investigative [24]
AP-24163 DMVT6Y3 Discovery agent N.A. Investigative [25]
AP-24226 DMGTEXD Discovery agent N.A. Investigative [25]
BAS-00387275 DMZPKGS Discovery agent N.A. Investigative [26]
BAS-00387328 DM4OSFD Discovery agent N.A. Investigative [26]
BAS-00387347 DMUF28Q Discovery agent N.A. Investigative [26]
BAS-00672722 DM6R4X8 Discovery agent N.A. Investigative [26]
BAS-01047341 DMNB7CW Discovery agent N.A. Investigative [26]
BAS-01047655 DMC0FLB Discovery agent N.A. Investigative [26]
BAS-01373578 DMZBIC3 Discovery agent N.A. Investigative [26]
BAS-0338868 DMZGLHJ Discovery agent N.A. Investigative [27]
BAS-0338872 DMZK0SC Discovery agent N.A. Investigative [27]
BAS-09534324 DMFMBZ9 Discovery agent N.A. Investigative [26]
BAS-450225 DMTH1JQ Discovery agent N.A. Investigative [26]
BAS-4844343 DMFNAKU Discovery agent N.A. Investigative [26]
BMS-279700 DMOLCFQ Discovery agent N.A. Investigative [28]
CGP 77675 DMXH2R3 Discovery agent N.A. Investigative [29]
CGP-191 DMCE6WJ Discovery agent N.A. Investigative [21]
CGP-62464 DMZ34P1 Discovery agent N.A. Investigative [21]
Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr DM67CAY Discovery agent N.A. Investigative [24]
Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe] DMB2DV1 Discovery agent N.A. Investigative [24]
Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr] DMO5V9M Discovery agent N.A. Investigative [24]
Cysteine Sulfenic Acid DM4GZUJ N. A. N. A. Investigative [30]
DPI59 DMTHZ3B Discovery agent N.A. Investigative [19]
Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu DM6EA9B Discovery agent N.A. Investigative [31]
Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu DMYZO37 Discovery agent N.A. Investigative [31]
HKI-9924129 DM5LR2B Gram-positive bacterial infection 1B74-1G40 Investigative [32]
ISO24 DMU64W8 Discovery agent N.A. Investigative [19]
JNJ-10198409 DM9GDP5 Discovery agent N.A. Investigative [33]
K00244 DM2BKU8 Discovery agent N.A. Investigative [34]
N-(4-(phenylamino)quinazolin-6-yl)acrylamide DMI74KM N. A. N. A. Investigative [19]
N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine DMGVJBD Discovery agent N.A. Investigative [28]
N6-Benzyl Adenosine-5'-Diphosphate DM71MO2 Discovery agent N.A. Investigative [35]
NG-25 DMC48D9 Discovery agent N.A. Investigative [36]
NM-PP1 DMS8H5Q Discovery agent N.A. Investigative [9]
Oxalic Acid DMLN2GQ Discovery agent N.A. Investigative [35]
PAS219 DML8BT7 Discovery agent N.A. Investigative [19]
PASBN DM7Y0G6 Discovery agent N.A. Investigative [19]
PD-0166326 DMD2CG9 Discovery agent N.A. Investigative [37]
PD-0173952 DMSCQ9U Discovery agent N.A. Investigative [32]
PD-0173955 DMOZEW9 Discovery agent N.A. Investigative [32]
PD-0173956 DM8RW92 Discovery agent N.A. Investigative [37]
PD-0173958 DMZQ8YV Discovery agent N.A. Investigative [32]
PD-0179483 DMKO8LE Discovery agent N.A. Investigative [32]
PD-174265 DMBHIAK Discovery agent N.A. Investigative [38]
PD173074 DMP0N4U Nasopharyngeal carcinoma 2B6B Investigative [18]
Phenylphosphate DMQ6P13 Discovery agent N.A. Investigative [30]
Phosphonotyrosine DM09MY1 Discovery agent N.A. Investigative [35]
PMID15546730C2 DMOPUIH Discovery agent N.A. Investigative [39]
PMID22765894C8h DMH5RFU Discovery agent N.A. Investigative [40]
PP121 DMU8KTO Discovery agent N.A. Investigative [41]
RU78191 DMOQE91 Discovery agent N.A. Investigative [19]
RU78262 DMR8I03 Discovery agent N.A. Investigative [19]
RU78299 DMXAK92 Discovery agent N.A. Investigative [19]
RU78300 DM27BKD Discovery agent N.A. Investigative [19]
RU78783 DMU5H4K Discovery agent N.A. Investigative [35]
RU79072 DM9GQP0 Discovery agent N.A. Investigative [19]
RU79073 DMWKTYC Discovery agent N.A. Investigative [19]
RU79256 DM06BGV Discovery agent N.A. Investigative [19]
RU81843 DMY3X6I Discovery agent N.A. Investigative [35]
RU82129 DMX7ZI0 Discovery agent N.A. Investigative [35]
RU82197 DMJG4RC Discovery agent N.A. Investigative [30]
RU82209 DMR3A2O Discovery agent N.A. Investigative [35]
RU83876 DMNGKYF Discovery agent N.A. Investigative [35]
RU84687 DMWK3LU Discovery agent N.A. Investigative [19]
RU85053 DMOA8FK Discovery agent N.A. Investigative [35]
RU85493 DM97ZHX Discovery agent N.A. Investigative [35]
RU90395 DMHFKUC Discovery agent N.A. Investigative [35]
SBB007833 DMU8KGB Discovery agent N.A. Investigative [42]
SKS-927 DMGQ9Z5 Discovery agent N.A. Investigative [43]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [9]
TG-100435 DMIR3X2 Discovery agent N.A. Investigative [44]
WH-4-023 DMJS8VQ Discovery agent N.A. Investigative [45]
Y-c[D-Pen-(2')Nal-GSFC]KR-NH2 DMAC65P Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2 DMEL4UN Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2 DM7P0H6 Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2 DMBNM85 Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2 DME1BGO Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2 DMF7S54 Discovery agent N.A. Investigative [46]
Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2 DMW1PSO Discovery agent N.A. Investigative [46]
Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2 DM2ILAH Discovery agent N.A. Investigative [46]
------------------------------------------------------------------------------------
⏷ Show the Full List of 98 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Glioma 2C82 Brainstem tissue 6.45E-01 -0.08 -0.58
Glioma 2C82 White matter 2.08E-03 -0.52 -1.62
Multiple myeloma 2C82 Bone marrow 7.46E-03 -0.2 -1.24
Breast cancer 2C82 Breast tissue 1.51E-04 -0.07 -0.28
Osteoporosis FA20 Bone marrow 4.20E-02 0.26 6.22
Neuroectodermal tumour 2C82 Nervous tissue 1.26E-29 -0.2 -0.64
Prostate cancer 2C82 Prostate 8.62E-01 -0.17 -0.45
Sarcoma 2C82 Muscle tissue 2.35E-48 -0.19 -0.78
------------------------------------------------------------------------------------
⏷ Show the Full List of DTT Expression Under 8 Diseases

References

1 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
8 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
9 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206).
11 Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
12 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
13 A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
14 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
15 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
16 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
17 Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9373-8.
18 Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
19 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
20 Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50.
21 Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
22 A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
23 Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
24 Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
25 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56.
26 A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
27 Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
28 Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85.
29 A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.
30 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
31 The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997).
32 Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
33 (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
34 The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
35 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
36 Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
37 Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
38 Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26.
39 Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
40 The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
41 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
42 Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.
43 Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1358-61.
44 Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
45 Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91.
46 Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.